Literature DB >> 8675591

Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.

J R Burgess1, J J Shepherd, V Parameswaran, L Hoffman, T M Greenaway.   

Abstract

Prolactinomas and somatotropinomas are reported to be the pituitary lesions most frequently associated with multiple endocrine neoplasia type 1 (MEN 1). However, few reports have documented the full spectrum of pituitary disease in this condition. We report herein the clinical, biochemical (PRL, alpha-subunit, insulin-like growth factor-I, cortisol, and thyroid function), and radiological (magnetic resonance imaging and computerized tomography scan) characteristics of pituitary disease occurring in a single MEN 1 pedigree containing 165 MEN 1-affected members. Pituitary lesions were detected in 30 (18%) of 165 patients overall. In the subgroup of MEN 1 patients (n = 131) living after recognition of MEN 1 in the kindred, pituitary lesions were detected in 25 (19%). In 76% of patients with pituitary lesions, the diagnosis was made by prospective screening; the remainder sought medical attention for symptomatic pituitary disease. Prolactinomas accounted for 76%, and nonfunctioning adenomas accounted for the remaining 24%. alpha-Subunit elevation was observed in 29% of 41 patients tested, and an aggressive alpha-subunit secreting macroadenoma developed in 1 subject with a previously documented prolactinoma. Progression of pituitary disease occurred in 47% of patients with prolactinoma. There were no cases of Cushing's disease, thyrotropinoma, or somatotropinoma. We conclude that 1) in addition to prolactinomas, nonfunctioning pituitary tumors are common in MEN 1; 2) alpha-subunit hypersecretion is frequent in MEN 1; 3) comprehensive screening may identify many clinically significant but asymptomatic pituitary lesions; and 4) prolactinomas occurring in MEN 1 may behave more aggressively than sporadic prolactinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675591     DOI: 10.1210/jcem.81.7.8675591

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  A new frameshift MEN1 gene mutation associated with familial malignant insulinomas.

Authors:  Shirin Hasani-Ranjbar; Mahsa M Amoli; Azadeh Ebrahim-Habibi; Mohammad Hossein Gozashti; Nahid Khalili; Forugh A Sayyahpour; Jila Hafeziyeh; Akbar Soltani; Bagher Larijani
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  MEN1 family with a novel frameshift mutation.

Authors:  V Nuzzo; L Tauchmanová; A Falchetti; A Faggiano; F Marini; S Piantadosi; M L Brandi; L Leopaldi; A Colao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 3.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

4.  Bilateral pituitary adenomas occurring with multiple endocrine neoplasia type one.

Authors:  A Sahdev; R Jäger
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

5.  Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels.

Authors:  Alina Livshits; Jelena Kravarusic; Ellie Chuang; Mark E Molitch
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

6.  Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?

Authors:  Jerena Manoharan; Friedhelm Raue; Caroline L Lopez; Max B Albers; Carmen Bollmann; Volker Fendrich; Emily P Slater; Detlef K Bartsch
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

7.  Ectopic Cushing syndrome associated with thymic carcinoid tumor as the first presentation of MEN1 syndrome-report of a family with MEN1 gene mutation.

Authors:  Shirin Hasani-Ranjbar; Masoud Rahmanian; Azadeh Ebrahim-Habibi; Akbar Soltani; Akbar Soltanzade; Elnaz Mahrampour; Mahsa M Amoli
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

8.  Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value.

Authors:  Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

Review 9.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

10.  Silent familial isolated pituitary adenomas: histopathological and clinical case report.

Authors:  C Villa; F Magri; P Morbini; A Falchetti; P Scagnelli; E Lovati; D Locatelli; F R Canevari; V Necchi; E Gabellieri; G Guabello; L Chiovato; E Solcia
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.